Bioburden: Everything about microbial contamination of products
Last updated: 05. May 2026
Bioburden is defined as the population of viable microorganisms on or within a product and/or a sterile barrier system. This includes mainly bacteria, fungi, and yeasts introduced from the environment, production processes, or human contact. It is typically measured on samples that have passed all manufacturing steps, including cleaning and packaging, and are ready for final sterilisation.
Bioburden determination is carried out using microbiological analytical methods in which existing microorganisms are extracted, cultured, and quantified as colony-forming units (CFU). A validated and regularly verified method is essential, since material properties and product design can affect microbial recovery.
A simple example: a surgical instrument is tested directly before packaging and sterilisation. If 150 CFU are detected, this value represents the bioburden. It serves as an indicator of whether the subsequent sterilisation process can reliably achieve a Sterility Assurance Level (SAL) of 10⁻⁶.
An elevated bioburden can increase the risk of infection and often indicates insufficiently controlled processes. Therefore, controlling and reducing microbial load is a key part of quality assurance, especially for medical devices.
Objectives of Bioburden testing
Bioburden testing determines the total number of viable microorganisms on a product before final sterilisation. It provides a key basis for assessing microbiological risk and ensuring product quality, particularly for medical devices.
At the same time, the test supports the design and control of sterilisation processes, for example in defining radiation doses, and acts as an early indicator of process deviations. Abnormal results may point to hygiene or process-related issues and help identify and prevent risks at an early stage.
Key questions and Challenges in Bioburden management
A major focus lies on developing suitable control strategies across the entire product lifecycle, from development to production. This includes defining which microorganisms should be monitored and at which process steps testing is appropriate, such as raw materials, manufacturing stages, or final products. Product-specific limits and the selection of suitable methods such as TAMC or TYMC are also important.
Other topics include the management of biofilms, microbiological assessment of raw materials, and the definition of warning and action limits. Additional aspects are sample stability, trend analysis, and handling deviations. In case of limit exceedances, root cause analysis and targeted microbial identification become central.
How Bioburden testing is performed
Bioburden testing follows a structured microbiological process designed to reliably detect and quantify microorganisms. The method is defined in ISO 11737-1 and forms the basis for evaluating microbial quality and validating sterilisation processes.
The steps are applied in sequence and adapted to the specific product:
1. Extraction (elution / microbial release)
Microorganisms are detached from the surface or interior of the product using validated mechanical or chemical methods (e.g. ultrasound, shaking, or rinsing) and transferred into a sterile liquid. It is ensured that all relevant surfaces, including hard-to-reach areas, are adequately covered.
2. Filtration
The obtained extract is filtered under sterile conditions to concentrate the microorganisms. Liquid samples may be cultured directly, while solid products are processed via membrane filtration (≤ 0.45 µm) or transferred into suitable culture media.
3. Cultivation & incubation
The membrane is placed on appropriate nutrient media and incubated under defined conditions. Typically, bacteria (TAMC) are incubated at 30–35 °C and yeasts/moulds (TYMC) at 20–25 °C for 3 to 7 days to allow visible colony formation.
4. Evaluation
Colony-forming units (CFU) are counted to determine the total microbial load.
5. Method validation
Extraction efficiency (recovery rate) is determined. Since no method can recover all microorganisms, a product-specific correction factor is established and applied to calculate the actual bioburden.
6. Evaluation & trend analysis
Results are assessed over time to monitor the manufacturing process and detect deviations early.
As a complementary approach, modern rapid microbiological methods (RMM) are used, enabling significantly shorter analysis times and serving as an efficient alternative to conventional methods.
Regulatory requirements and Standards
Control of microbial contamination is a fundamental regulatory requirement in medical device and pharmaceutical manufacturing. The EU Medical Device Regulation MDR (EU) 2017/745 requires under the General Safety and Performance Requirements (GSPR 11) that products and manufacturing processes are designed to minimise the risk of microbial contamination. This applies to both sterile and non-sterile products and includes requirements for cleaning, disinfection, sterilisation, and packaging systems.
Relevant standards and guidelines define specific requirements for implementation and compliance:
- ISO 13485: Quality management and process control
- ISO 11737-1: Determination of bioburden
- ISO 17665 (steam), ISO 11135 (EO), ISO 11137-1 (radiation): Validation of sterilisation processes
- 21 CFR 211: In-process controls in manufacturing
Pharmaceutical manufacturers additionally follow pharmacopoeias (e.g. Ph. Eur. 2.6.12) and EU GMP Annex 1 to ensure microbiological quality.
All regulations require a system for microbial quality control with defined limits and corrective actions. Bioburden determination is therefore a central element of quality assurance, supporting sterilisation validation, process monitoring, regulatory compliance, and the safety of patients and users.